p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer
Corresponding Author
Anita Koushik
Department of Nutrition, Harvard School of Public Health, Boston, MA
Fax: +617-432-2435
Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Building 2, Room 321, Boston, MA 02115, USASearch for more papers by this authorGregory J. Tranah
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Search for more papers by this authorJing Ma
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorMeir J. Stampfer
Department of Nutrition, Harvard School of Public Health, Boston, MA
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorHoward D. Sesso
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorCharles S. Fuchs
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorEdward L. Giovannucci
Department of Nutrition, Harvard School of Public Health, Boston, MA
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorDavid J. Hunter
Department of Nutrition, Harvard School of Public Health, Boston, MA
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorCorresponding Author
Anita Koushik
Department of Nutrition, Harvard School of Public Health, Boston, MA
Fax: +617-432-2435
Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Building 2, Room 321, Boston, MA 02115, USASearch for more papers by this authorGregory J. Tranah
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Search for more papers by this authorJing Ma
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorMeir J. Stampfer
Department of Nutrition, Harvard School of Public Health, Boston, MA
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorHoward D. Sesso
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorCharles S. Fuchs
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorEdward L. Giovannucci
Department of Nutrition, Harvard School of Public Health, Boston, MA
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorDavid J. Hunter
Department of Nutrition, Harvard School of Public Health, Boston, MA
Department of Epidemiology, Harvard School of Public Health, Boston, MA
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Search for more papers by this authorAbstract
A single nucleotide polymorphism (SNP) at codon 72 of the p53 gene (Arg72Pro) alters the p53 protein structure and affects its activity. We investigated this SNP in relation to colorectal adenoma and cancer among men and women from case–control studies nested within the Nurses' Health Study, the Health Professionals Follow-up Study and the Physicians' Health Study. Among 856 colorectal adenoma cases and 1,184 controls, we observed a modest association with p53 Arg72Pro genotype (multivariate odds ratio (OR) = 1.25, 95% confidence interval (CI) = 1.04–1.50 for Arg/Pro and Pro/Pro vs. Arg/Arg). This association did not vary by colorectal site or by sex. Among 442 colorectal cancer cases and 904 controls, we observed no significant overall association between p53 Arg72Pro genotype and colorectal cancer (multivariate OR = 1.14, 95% CI = 0.90–1.45). However, when colorectal site and sex was accounted for, the Pro carrier genotypes compared to Arg/Arg were associated with an increased risk of proximal colon cancers in women (multivariate OR = 2.59, 95% CI = 1.49–4.52) though not with distal colon or rectal cancers, while among men the same genotypes were associated with an increased risk of distal colon cancers (multivariate OR = 2.09, 95% CI = 1.28–3.40) but not proximal colon or rectal cancers. Our results suggest that Arg72Pro may play a role in the early stages of colorectal neoplasia and possibly in progression to invasive disease, depending on site and sex. © 2006 Wiley-Liss, Inc.
References
- 1
Prives C,
Hall PA.
The p53 pathway.
J Pathol
1999;
187:
112–26.
10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 2 Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594–604.
- 3 Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7: 961–3.
- 4 Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092–100.
- 5 Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229–34.
- 6 Dumont P, Leu JI, Della Pietra AC,III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357–65.
- 7 Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108: 196–9.
- 8 Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525–32.
- 9 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67.
- 10 Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 1991; 86: 369–70.
- 11 Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993; 14: 1085–9.
- 12 Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L, Beckman G. p53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995; 16: 1461–4.
- 13 Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996; 17: 261–4.
- 14 Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. p53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001; 109: 25–34.
- 15 Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 23: 1954–6.
- 16 Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098–102.
- 17 Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, Hunter DJ. Epoxide hydrolase polymorphisms, cigarette smoking and risk ofcolorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study. Carcinogenesis 2004; 25: 1211–18.
- 18 Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hunter DJ. APC Asp1822Val and Gly2502Ser polymorphisms and risk of colorectal cancer and adenoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 863–70.
- 19 Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14: 143–9.
- 20 Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: M Egger, GD Smith, DG Altman, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ, 2001. 285–312.
- 21 Chen J, Hunter DJ, Stampfer MJ, Kyte C, Chan W, Wetmur JG, Mosig R, Selhub J, Ma J. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 958–62.
- 22 Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004; 13: 11–22.
- 23 Jee SH, Won SY, Yun JE, Lee JE, Park JS, Ji SS. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 2004; 85: 301–8.
- 24 Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003; 18: 377–85.
- 25 Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004; 130: 728–32.
- 26 Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113: 779–88.
- 27 Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002; 101: 403–8.
- 28 Gervaz P, Bucher P, Morel P. Two colons–two cancers: paradigm shift and clinical implications. J Surg Oncol 2004; 88: 261–6.
- 29
Breivik J,
Lothe RA,
Meling GI,
Rognum TO,
Borresen-Dale AL,
Gaudernack G.
Different genetic pathways to proximal and distalcolorectal cancer influenced by sex-related factors.
Int J Cancer
1997;
74:
664–9.
10.1002/(SICI)1097-0215(19971219)74:6<664::AID-IJC18>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 30 Bonithon-Kopp C, Benhamiche AM. Are there several colorectal cancers? Epidemiological data. Eur J Cancer Prev 1999; 8 ( Suppl 1): S3–S12.
- 31 Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gender-Based Med 1999; 8: 1155–66.
- 32 Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266–70.
- 33 Sjalander A, Birgander R, Kivela A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995; 45: 144–9.
- 34 Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2000; 92: 1151–8.
Citing Literature
